Research article

Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer

Greg M Arndt^1,5 , Lesley Dossey² , Lara M Cullen¹ , Angela Lai¹ , Riki Druker¹ , Michael Eisbacher¹ , Chunyan Zhang¹ , Nham Tran¹ , Hongtao Fan³ , Kathy Retzlaff⁴ , Anton Bittner⁴ and Mitch Raponi³

¹  Johnson and Johnson Research Pty Ltd, Eveleigh, NSW, Australia

²  Veridex L.L.C., a Johnson and Johnson company, San Diego, CA, USA

³  Centocor Research & Development, Inc., Radnor, PA, USA

⁴  Johnson & Johnson Pharmaceutical Research & Development L.L.C., San Diego, CA, USA

⁵  Children's Cancer Institute Australia for Medical Research, PO Box 81 (High Street), Randwick, Sydney, NSW 2031, Australia

author email corresponding author email

BMC Cancer 2009, 9:374doi:10.1186/1471-2407-9-374

Published:	20 October 2009

Abstract

Background

MicroRNAs (MiRNAs) are short non-coding RNAs that control protein expression through various mechanisms. Their altered expression has been shown to be associated with various cancers. The aim of this study was to profile miRNA expression in colorectal cancer (CRC) and to analyze the function of specific miRNAs in CRC cells. MirVana miRNA Bioarrays were used to determine the miRNA expression profile in eight CRC cell line models, 45 human CRC samples of different stages, and four matched normal colon tissue samples. SW620 CRC cells were stably transduced with miR-143 or miR-145 expression vectors and analyzed in vitro for cell proliferation, cell differentiation and anchorage-independent growth. Signalling pathways associated with differentially expressed miRNAs were identified using a gene set enrichment analysis.

Results

The expression analysis of clinical CRC samples identified 37 miRNAs that were differentially expressed between CRC and normal tissue. Furthermore, several of these miRNAs were associated with CRC tumor progression including loss of miR-133a and gain of miR-224. We identified 11 common miRNAs that were differentially expressed between normal colon and CRC in both the cell line models and clinical samples. In vitro functional studies indicated that miR-143 and miR-145 appear to function in opposing manners to either inhibit or augment cell proliferation in a metastatic CRC model. The pathways targeted by miR-143 and miR-145 showed no significant overlap. Furthermore, gene expression analysis of metastatic versus non-metastatic isogenic cell lines indicated that miR-145 targets involved in cell cycle and neuregulin pathways were significantly down-regulated in the metastatic context.

Conclusion

MiRNAs showing altered expression at different stages of CRC could be targets for CRC therapies and be further developed as potential diagnostic and prognostic analytes. The identified biological processes and signalling pathways collectively targeted by co-expressed miRNAs in CRC provide a basis for understanding the functional role of miRNAs in cancer.